Feb 22, 2024
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Feb 15, 2024
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Feb 01, 2024
Immunic to Participate in Investor and Scientific Conferences in February
Jan 05, 2024
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Feb 11, 2021
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
Nov 24, 2020
Immunic, Inc. to Participate in Investor Conferences in December
Nov 17, 2020
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
Nov 10, 2020
Immunic, Inc. to Participate in Investor and Scientific Conferences in November
Sep 29, 2020
Immunic, Inc. to Participate in Scientific Conferences in October
Sep 28, 2020
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
Sep 11, 2020
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
Aug 10, 2020
Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 03, 2020
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
Jul 30, 2020
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Jul 29, 2020
Immunic, Inc. to Participate in Investor Conferences in August
Jun 22, 2020
Immunic, Inc. to Join Russell 3000® Index
Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 10, 2020
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Jun 09, 2020
Immunic, Inc. Announces Proposed Public Offering of Common Stock
Apr 21, 2020
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients